- Details
- Irene Burger discusses the significant impact of PSMA PET in diagnosing high-risk localized prostate cancer. Dr. Burger describes the rapid adoption of this technology in Switzerland, emphasizing its enhanced sensitivity over traditional imaging since its integration in 2016. Dr. Burger highlights the broad acceptance and crucial insights from significant studies, such as the proPSMA trial, which...
|
- Details
- Jeffrey Tosoian presents a new tool in prostate cancer diagnosis with the development and validation of an 18-gene urine test designed to identify clinically significant prostate cancer published in JAMA Oncology. This research, supported by the Prostate Cancer Foundation (PCF) and the NCI Early Detection Research Network, introduces a novel approach to enhancing the accuracy of prostate cancer de...
|
- Details
- Men with localized or locally advanced prostate cancer (LPC/LAPC) are at risk of progression after radiotherapy (RT) or radical prostatectomy (RP). Using real-world data, we evaluated patient characteristics, treatment patterns, and outcomes in LPC/LAPC. Biographies: Stephen J. Freedland, MD, Urologist, Cedars-Sinari, Los Angeles, CA, Staff Physician, Durham VA Medical Center, Durham, NC. Related...
|
- Details
- Alicia Morgans hosts Daniel Barocas and Bashir Al Hussein Al Awamlh to discuss findings from the CEASAR study published in JAMA, which explores long-term quality of life outcomes for men with localized prostate cancer. Initiated by Dave Penson, this longitudinal study aims to enhance shared decision-making in treatment by providing data on the side effects of various prostate cancer treatments. Fo...
|
- Details
- Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Zachary Klaassen, MD, MSc, Urologic Oncologist, Assistant Professor Surgery/Urology at the Medical College of Georgia at Augusta University, Well Star MCG, Georgia Cancer Center, Augusta, GA Neal D. Sh...
|
- Details
- At the 2024 PSMA Conference PSMA PET and RLT: Present and Future, Louise Emmett explores enhancing prostate cancer diagnosis with PSMA PET imaging, revealing the PRIMARY trials' findings that combining PSMA PET with MRI significantly improves the accuracy of detecting clinically significant malignancies. Dr. Emmett introduces the PRIMARY score for interpreting PSMA PET results and discusses ongoin...
|
- Details
- Alicia Morgans talks with Mack Roach about his research in radiation oncology and urology. Dr. Roach discusses his involvement in studies like RTOG 75-06, 86-10, and 85-31, focusing on hormones and radiation in prostate cancer. He shares insights from his analysis of pre-treatment testosterone data from 2,400 patients, revealing that age over 70 correlates with better prostate cancer-specific outc...
|
- Details
- Ruchika Talwar hosts Joshua Cabral and Yaw Nyame to explore the impact of mental health disorders on prostate cancer care. Their study, "Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders," used the Medicare database from 2004 to 2015. They found that 50% of US adults meet DSM-IV disorder criteria at some point, and ment...
|
- Details
- Neil Desai and Paul Nguyen discuss the integration of the Decipher® genomic biomarker in prostate cancer treatment. The conversation centers on two trials, NRG-GU009 and GU010, which utilize Decipher® genomic classifiers to tailor treatment intensity, particularly in hormonal therapy. Dr. Nguyen emphasizes the shift from traditional metrics like PSA and Gleason scores to more precise genomic class...
|
- Details
- Zach Klaassen converses with Matthew Cooperberg about findings from the EMBARK study, presented at ESMO and published in the New England Journal. The study focuses on the efficacy of enzalutamide (enza) plus leuprolide versus leuprolide alone in treating high-risk non-metastatic hormone-sensitive prostate cancer. Dr. Cooperberg notes the predictability of better efficacy with combination treatment...
|
